Optimizing R/R CLL Treatment: Therapy Sequencing and Supportive Care Strategies - Episode 6
Panelists discuss how the non-covalent BTK inhibitor pirtobrutinib has shown promising results in the BRUIN clinical trials for both BTK inhibitor-naive and previously treated chronic lymphocytic leukemia patients, reviewing key efficacy and safety data presented at recent hematology conferences.
Video content above is prompted by the following: